Anupam Rasayan India Ltd (ANURAS) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Anupam Rasayan reported considerable revenue growth in Q4 FY25, reaching 506 crores, a 22% YoY and 31% QoQ increase.
- Full-year FY25 revenue stood at 1448 crores, a decline of 4% YoY, attributed to weak macro conditions in the first half.
- Margins remained consistent in Q4, driven by operational efficiency and a favorable product mix.
- The second half of FY25 showed significant improvement, with Q4 marking a positive turn in momentum.
- Pharma and polymer segments were strong contributors, aligning with the company's strategy to diversify its revenue base.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.